Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Endocrine disorders – page 34

  • 504 clinical trials
  • 189 recruiting
  • 213 conditions
  • 25 countries

Conditions in this area

213 conditions with trials, the busiest first

Type 2 diabetes mellitus85Type 1 diabetes mellitus41Endocrine ophthalmopathy26Neuroblastoma26Obesity24Diabetes mellitus21Neuroendocrine tumour19Overweight18Gastroenteropancreatic neuroendocrine tumour disease16Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Myotonic dystrophy12Adrenogenital syndrome11Neuroendocrine carcinoma11Thyroid cancer11Graves' disease10Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Chronic kidney disease8Glucose tolerance impaired7Pancreatic neuroendocrine tumour7Adrenocortical carcinoma6+189

Clinical trials in Endocrine disorders

504 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

504 clinical trials

Adrenoleukodystrophy

Not recruiting

Study on the Safety and Effectiveness of SBT101 Gene Therapy for Adults with Adrenomyeloneuropathy

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Adeno-Associated Viral Vector Serotype 9 Containing The Human Habcd1 Gene
  • Sponsor:Swanbio Therapeutics Limited

Wolfram syndrome

Not recruiting

Study on the Effects of Sodium Valproate for Hearing Preservation in Patients with Wolfram Syndrome

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Sodium Valproate
  • Sponsor:Centre D'Etude Des Cellules Souches

Adrenoleukodystrophy

Not recruiting

Study on the Effects of Dimethyl Fumarate for Patients with Adrenomyeloneuropathy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Dimethyl Fumarate
  • Sponsor:Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Bulbospinal muscular atrophy congenital

Not recruiting

Study of NIDO-361 for Patients with Spinal and Bulbar Muscular Atrophy (SBMA)

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:NIDO-361
  • Sponsor:Nido Biosciences Inc.

Type 2 diabetes mellitus

Not recruiting

Study Comparing Orforglipron and Dapagliflozin for Adults with Type 2 Diabetes and Poor Blood Sugar Control on Metformin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Eli Lilly & Co.

Type 2 diabetes mellitus

Not recruiting

Study of Orforglipron for Adults with Type 2 Diabetes and Poor Blood Sugar Control on Insulin Glargine, with or without Metformin and/or SGLT-2 Inhibitor

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Eli Lilly & Co.

Diabetic neuropathy

Not recruiting

Study of LY3556050 for Adults with Diabetic Peripheral Neuropathy Pain

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:LY3556050
  • Sponsor:Eli Lilly & Co.

Endocrine ophthalmopathy

Not recruiting

Study on the Safety and Effectiveness of LASN01 for Patients with Thyroid Eye Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LASN01
  • Sponsor:Lassen Therapeutics 1 Inc.

Thyroid cancer

Not recruiting

Study on Cabozantinib for Patients with Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Grupo Espanol De Tumores Neuroendocrinos

Neuroendocrine carcinoma

Not recruiting

Study of daily low-dose temozolomide in patients with advanced neuroendocrine tumors (NETs) who are not eligible for standard treatments due to their health condition

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study on RYZ101 for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors After Previous Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Everolimus
  • Sponsor:Rayzebio Inc.

Primary hyperaldosteronism

Not recruiting

Study on [68Ga]Ga-PentixaFor PET Imaging for Identifying Unilateral Adrenal Aldosterone Secretion in Patients with Primary Aldosteronism

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gallium (68GA)
  • Sponsor:Assistance Publique Hopitaux De Paris

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Semaglutide48 clinical trialsDapagliflozin21 clinical trialsEmpagliflozin14 clinical trialsMetformin Hydrochloride13 clinical trialsMetformin12 clinical trialsSodium Chloride12 clinical trialsCisplatin11 clinical trialsEtoposide11 clinical trialsLutetium (177LU) oxodotreotide11 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.